GlassScriptPhysician profile
Rahil Shah
NPI 1194495085
$4,905.75
in general payments reported to CMS, 2019-2025
33 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.28 · 2022: $762 · 2023: $639 · 2024: $3,036 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634 · Consulting Fee: $1,320 · Long Term Medical Supply Or Device Loan: $665 · Travel and Lodging: $342 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.32 |
| Consulting Fee | $1,320.00 |
| Long Term Medical Supply Or Device Loan | $665.16 |
| Travel and Lodging | $341.98 |
| Education | $115.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $2,299.56 | 2022-2024 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $797.96 | 2022-2025 | |
| Janssen Biotech, INC. | $265.53 | 2023-2025 | Tecvayli, Darzalex, Carvykti |
| Astrazeneca Pharmaceuticals LP | $191.55 | 2021-2023 | Imfinzi |
| Adaptive Biotechnologies Corporation | $172.81 | 2023-2025 | Clonoseq |
| Sobi, INC | $140.13 | 2023-2024 | |
| Gilead Sciences, INC. | $100.03 | 2022 | |
| Abbvie INC. | $96.09 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $84.14 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $74.25 | 2022-2025 | Opdivo |
| Karyopharm Therapeutics INC. | $63.00 | 2022-2024 | Xpovio |
| Servier Pharmaceuticals LLC | $53.43 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.18 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $41.75 | 2022-2024 | |
| Amgen INC. | $38.24 | 2022-2023 | Lumakras |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.84 | 2023-2024 | Alunbrig, Fruzaqla |
| Inari Medical, INC. | $33.27 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $32.37 | 2024 | Osteocool Rf Ablation System |
| Celgene Corporation | $29.34 | 2023 | Pomalyst |
| Pharmaessentia USA Corporation | $28.83 | 2023 | Besremi |
| Rigel Pharmaceuticals, INC. | $27.90 | 2023 | Tavalisse, Rezlidhia |
| Geron Corporation | $27.25 | 2025 | Rytelo |
| Glaxosmithkline, LLC. | $26.70 | 2025 | Blenrep |
| Blueprint Medicines Corporation | $26.33 | 2021 | |
| G1 Therapeutics, INC. | $25.44 | 2023 | Cosela |
| Nuvation Bio INC. | $23.99 | 2025 | Ibtrozi |
| Beigene USA, INC. | $23.13 | 2022 | |
| Tempus Ai, INC | $20.12 | 2024 | |
| Genzyme Corporation | $19.83 | 2023 | |
| Genmab U.S., INC. | $19.13 | 2023 | Tivdak |
| Merck Sharp & Dohme LLC | $17.83 | 2024 | Keytruda |
| Pfizer INC. | $14.18 | 2025 | |
| Daiichi Sankyo INC. | $13.62 | 2023 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahil Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.